MiRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies

Advanced Drug Delivery Reviews

Volumn 81, Issue , 2015, Pages 34-52

  Chitkara, Deepak ^a   Mittal, Anupama ^a   Mahato, Ram I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cationic carriers; Chemical modifications; Chemoresistance; Desmoplasia; EMT; MiRNA

Indexed keywords

CHEMICAL MODIFICATION; DIAGNOSIS; DISEASES; GENE EXPRESSION; GENES;

CHEMORESISTANCE; DESMOPLASIA; DUCTAL ADENOCARCINOMAS; EMT; MIRNA; NATIONAL CANCER INSTITUTE; PHYSICOCHEMICAL PROPERTY; THERAPEUTIC POTENTIALS;

RNA;

DOXORUBICIN; GEMCITABINE; LIPID; MACROGOL; MICRORNA; MICRORNA 205; NANOPARTICLE; NOTCH RECEPTOR; POLYESTER; POLYETHYLENEIMINE; POLYMER; MESSENGER RNA;

CARCINOGENESIS; CONJUGATION; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC VARIABILITY; HUMAN; MOLECULAR PATHOLOGY; NANOENCAPSULATION; NONHUMAN; PANCREAS ADENOCARCINOMA; REVIEW; RNA CLEAVAGE; RNA DEGRADATION; RNA SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PANCREATIC NEOPLASMS; PROGNOSIS; RNA, MESSENGER;

EID: 84922246577     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.09.006     Document Type: Review

References (239)

1. American Cancer Society, Pancreatic Cancer, 2014 (2014) 01.
2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
3. Matsuno S., Egawa S., Fukuyama S., Motoi F., Sunamura M., Isaji S., Imaizumi T., Okada S., Kato H., Suda K., Nakao A., Hiraoka T., Hosotani R., Takeda K. Pancreatic Cancer Registry in Japan: 20years of experience. Pancreas 2004, 28:219-230.
4. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N., Harris M., Reni M., Dowden S., Laheru D., Bahary N., Ramanathan R.K., Tabernero J., Hidalgo M., Goldstein D., Van Cutsem E., Wei X., Iglesias J., Renschler M.F. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013, 369:1691-1703.
5. Reni M., Wan Y., Solem C., Whiting S., Ji X., Botteman M. Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. J. Med. Econ. 2014, 17:338-346.
6. Portal A., Pernot S., Siauve N., Landi B., Lepere C., Colussi O., Rougier P., Zaanan A., Verriere B., Taieb J. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Clin. Res. Hepatol. Gastroenterol. 2014, 38:e23-e26.
7. Porter C.E., Waddell J.A., Solimando D.A. Nab-paclitaxel plus gemcitabine regimen for pancreatic cancer. Hosp. Pharm. 2014, 49:18-22.
8. Diaz Beveridge R., Alcolea V., Aparicio J., Segura A., Garcia J., Corbellas M., Fonfria M., Gimenez A., Montalar J. Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice. JOP 2014, 15:19-24.
9. Park S., Chung M.J., Park J.Y., Chung J.B., Bang S., Park S.W., Song S.Y. Phase II trial of erlotinib plus gemcitabine chemotherapy in Korean patients with advanced pancreatic cancer and prognostic factors for chemotherapeutic response. Gut Liver 2013, 7:611-615.
10. Vaccaro V., Bria E., Sperduti I., Gelibter A., Moscetti L., Mansueto G., Ruggeri E.M., Gamucci T., Cognetti F., Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J. Gastroenterol. 2013, 19:4511-4519.
11. Awasthi N., Schwarz M.A., Schwarz R.E. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB (Oxford) 2011, 13:597-604.
12. Casneuf V.F., Demetter P., Boterberg T., Delrue L., Peeters M., Van Damme N. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol. Rep. 2009, 22:105-113.
13. Tran Cao H.S., Bouvet M., Kaushal S., Keleman A., Romney E., Kim G., Fruehauf J., Imagawa D.K., Hoffman R.M., Katz M.H. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol. Cancer Ther. 2010, 9:2068-2078.
14. Costello B.A., Borad M.J., Qi Y., Kim G.P., Northfelt D.W., Erlichman C., Alberts S.R. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest. New Drugs 2014, 32:710-716.
15. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., Bennouna J., Bachet J.B., Khemissa-Akouz F., Pere-Verge D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M., Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364:1817-1825.
16. Cheng H., Shi S., Cai X., Long J., Xu J., Liu C., Yu X. MicroRNA signature for human pancreatic cancer invasion and metastasis. Exp. Ther. Med. 2012, 4:181-187.
17. Frampton A.E., Castellano L., Colombo T., Giovannetti E., Krell J., Jacob J., Pellegrino L., Roca-Alonso L., Funel N., Gall T.M., De Giorgio A., Pinho F.G., Fulci V., Britton D.J., Ahmad R., Habib N.A., Coombes R.C., Harding V., Knosel T., Stebbing J., Jiao L.R. MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology 2014, 146:268-277. (e18).
18. Gnoni A., Licchetta A., Scarpa A., Azzariti A., Brunetti A.E., Simone G., Nardulli P., Santini D., Aieta M., Delcuratolo S., Silvestris N. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int. J. Mol. Sci. 2013, 14:19731-19762.
19. Zhang R., Li M., Zang W., Chen X., Wang Y., Li P., Du Y., Zhao G., Li L. MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour Biol. 2014, 35:837-844.
20. Lahdaoui F., Delpu Y., Vincent A., Renaud F., Messager M., Duchene B., Leteurtre E., Mariette C., Torrisani J., Jonckheere N., Van Seuningen I. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene 2014, 0:1-9.
21. Gao W., Gu Y., Li Z., Cai H., Peng Q., Tu M., Kondo Y., Shinjo K., Zhu Y., Zhang J., Sekido Y., Han B., Qian Z., Miao Y. miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene 2014, 0. 10.1038/onc.2014.101.
22. Groher F., Suess B. Synthetic riboswitches - a tool comes of age. Biochim. Biophys. Acta 2014, 1839:964-973.
23. Kanwar J.R., Mohan R.R., Kanwar R.K., Roy K., Bawa R. Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine (London) 2010, 5:1435-1445.
24. Helene C. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. Anticancer Drug Des. 1991, 6:569-584.
25. Yang N., Singh S., Mahato R.I. Targeted TFO delivery to hepatic stellate cells. J. Control. Release 2011, 155:326-330.
26. Scott W.G., Horan L.H., Martick M. The hammerhead ribozyme: structure, catalysis, and gene regulation. Prog. Mol. Biol. Transl. Sci. 2013, 120:1-23.
27. Schubert S., Kurreck J. Ribozyme- and deoxyribozyme-strategies for medical applications. Curr. Drug Targets 2004, 5:667-681.
28. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
29. Mack G.S. MicroRNA gets down to business. Nat. Biotechnol. 2007, 25:631-638.
30. Kiryu H., Terai G., Imamura O., Yoneyama H., Suzuki K., Asai K. A detailed investigation of accessibilities around target sites of siRNAs and miRNAs. Bioinformatics 2011, 27:1788-1797.
31. Ling H., Fabbri M., Calin G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 2013, 12:847-865.
32. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
33. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., Croce C.M. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15524-15529.
34. Zhang Y., Wang Z., Gemeinhart R.A. Progress in microRNA delivery. J. Control. Release 2013, 172:962-974.
35. Liu X.Q., Song W.J., Sun T.M., Zhang P.Z., Wang J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol. Pharm. 2011, 8:250-259.
36. Whatcott C.J., Han H., Posner R.G., Hostetter G., Von Hoff D.D. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011, 1:291-296.
37. Kozono S., Ohuchida K., Eguchi D., Ikenaga N., Fujiwara K., Cui L., Mizumoto K., Tanaka M. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 2013, 73:2345-2356.
38. Hu Q.L., Jiang Q.Y., Jin X., Shen J., Wang K., Li Y.B., Xu F.J., Tang G.P., Li Z.H. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 2013, 34:2265-2276.
39. Chiou G.Y., Cherng J.Y., Hsu H.S., Wang M.L., Tsai C.M., Lu K.H., Chien Y., Hung S.C., Chen Y.W., Wong C.I., Tseng L.M., Huang P.I., Yu C.C., Hsu W.H., Chiou S.H. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J. Control. Release 2012, 159:240-250.
40. Yang Y.P., Chien Y., Chiou G.Y., Cherng J.Y., Wang M.L., Lo W.L., Chang Y.L., Huang P.I., Chen Y.W., Shih Y.H., Chen M.T., Chiou S.H. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 2012, 33:1462-1476.
41. Hwang do W., Son S., Jang J., Youn H., Lee S., Lee D., Lee Y.S., Jeong J.M., Kim W.J., Lee D.S. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011, 32:4968-4975.
42. Baigude H., Rana T.M. Interfering nanoparticles for silencing microRNAs. Methods Enzymol. 2012, 509:339-353.
43. Pramanik D., Campbell N.R., Karikari C., Chivukula R., Kent O.A., Mendell J.T., Maitra A. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 2011, 10:1470-1480.
44. Shi S., Han L., Gong T., Zhang Z., Sun X. Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew. Chem. Int. Ed. Engl. 2013, 52:3901-3905.
45. Chen Y., Zhu X., Zhang X., Liu B., Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 2010, 18:1650-1656.
46. Craig V.J., Tzankov A., Flori M., Schmid C.A., Bader A.G., Muller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 2012, 26:2421-2424.
47. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., Weidhaas J.B., Bader A.G., Slack F.J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19:1116-1122.
48. Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Patrawala L., Brown D., Bader A.G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70:5923-5930.
49. Di Martino M.T., Campani V., Misso G., Gallo Cantafio M.E., Gulla A., Foresta U., Guzzi P.H., Castellano M., Grimaldi A., Gigantino V., Franco R., Lusa S., Cannataro M., Tagliaferri P., De Rosa G., Tassone P., Caraglia M. In vivo activity of MiR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS ONE 2014, 9:e90005.
50. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
51. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
52. Miyamoto Y., Maitra A., Ghosh B., Zechner U., Argani P., Iacobuzio-Donahue C.A., Sriuranpong V., Iso T., Meszoely I.M., Wolfe M.S., Hruban R.H., Ball D.W., Schmid R.M., Leach S.D. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3:565-576.
53. Sarkar F.H., Banerjee S., Li Y. Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol. Appl. Pharmacol. 2007, 224:326-336.
54. Wang Z., Banerjee S., Li Y., Rahman K.M., Zhang Y., Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006, 66:2778-2784.
55. Wang Z., Zhang Y., Li Y., Banerjee S., Liao J., Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 2006, 5:483-493.
56. Buchler P., Gazdhar A., Schubert M., Giese N., Reber H.A., Hines O.J., Giese T., Ceyhan G.O., Muller M., Buchler M.W., Friess H. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann. Surg. 2005, 242:791-800. (discussion 800-1).
57. Bao B., Wang Z., Ali S., Kong D., Li Y., Ahmad A., Banerjee S., Azmi A.S., Miele L., Sarkar F.H. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011, 307:26-36.
58. Schutte M., Hruban R.H., Geradts J., Maynard R., Hilgers W., Rabindran S.K., Moskaluk C.A., Hahn S.A., Schwarte-Waldhoff I., Schmiegel W., Baylin S.B., Kern S.E., Herman J.G. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997, 57:3126-3130.
59. Li Y., Bhuiyan M., Vaitkevicius V.K., Sarkar F.H. Molecular analysis of the p53 gene in pancreatic adenocarcinoma. Diagn. Mol. Pathol. 1998, 7:4-9.
60. Cowgill S.M., Muscarella P. The genetics of pancreatic cancer. Am. J. Surg. 2003, 186:279-286.
61. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 2006, 12:5268-5272.
62. Chadha K.S., Khoury T., Yu J., Black J.D., Gibbs J.F., Kuvshinoff B.W., Tan D., Brattain M.G., Javle M.M. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann. Surg. Oncol. 2006, 13:933-939.
63. Yang S.H., Hsu C.H., Lee J.C., Tien Y.W., Kuo S.H., Cheng A.L. Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-kappaB is associated with a poor prognosis of pancreatic cancer. Oncology 2013, 85:86-94.
64. Algul H., Adler G., Schmid R.M. NF-kappaB/Rel transcriptional pathway: implications in pancreatic cancer. Int. J. Gastrointest. Cancer 2002, 31:71-78.
65. Sclabas G.M., Fujioka S., Schmidt C., Evans D.B., Chiao P.J. NF-kappaB in pancreatic cancer. Int. J. Gastrointest. Cancer 2003, 33:15-26.
66. Maniati E., Bossard M., Cook N., Candido J.B., Emami-Shahri N., Nedospasov S.A., Balkwill F.R., Tuveson D.A., Hagemann T. Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. J. Clin. Invest. 2011, 121:4685-4699.
67. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernandez-del Castillo C., Yajnik V., Antoniu B., McMahon M., Warshaw A.L., Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
68. Singh B.N., Fu J., Srivastava R.K., Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS ONE 2011, 6:e27306.
69. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
70. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 2005, 6:376-385.
71. Brennecke J., Hipfner D.R., Stark A., Russell R.B., Cohen S.M. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003, 113:25-36.
72. Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75:855-862.
73. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., Horvitz H.R., Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901-906.
74. Johnston R.J., Hobert O. A microRNA controlling left/right neuronal asymmetry in Caenorhabditis elegans. Nature 2003, 426:845-849.
75. Xu P., Vernooy S.Y., Guo M., Hay B.A. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr. Biol. 2003, 13:790-795.
76. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
77. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B., MacDougald O.A., Cho K.R., Fearon E.R. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17:1298-1307.
78. Corney D.C., Flesken-Nikitin A., Godwin A.K., Wang W., Nikitin A.Y. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007, 67:8433-8438.
79. Zhang L., Volinia S., Bonome T., Calin G.A., Greshock J., Yang N., Liu C.G., Giannakakis A., Alexiou P., Hasegawa K., Johnstone C.N., Megraw M.S., Adams S., Lassus H., Huang J., Kaur S., Liang S., Sethupathy P., Leminen A., Simossis V.A., Sandaltzopoulos R., Naomoto Y., Katsaros D., Gimotty P.A., DeMichele A., Huang Q., Butzow R., Rustgi A.K., Weber B.L., Birrer M.J., Hatzigeorgiou A.G., Croce C.M., Coukos G. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7004-7009.
80. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., Jones P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9:435-443.
81. Scott G.K., Mattie M.D., Berger C.E., Benz S.C., Benz C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006, 66:1277-1281.
82. Calin G.A., Liu C.G., Sevignani C., Ferracin M., Felli N., Dumitru C.D., Shimizu M., Cimmino A., Zupo S., Dono M., Dell'Aquila M.L., Alder H., Rassenti L., Kipps T.J., Bullrich F., Negrini M., Croce C.M. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11755-11760.
83. Muralidhar B., Goldstein L.D., Ng G., Winder D.M., Palmer R.D., Gooding E.L., Barbosa-Morais N.L., Mukherjee G., Thorne N.P., Roberts I., Pett M.R., Coleman N. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J. Pathol. 2007, 212:368-377.
84. Chiosea S., Jelezcova E., Chandran U., Luo J., Mantha G., Sobol R.W., Dacic S. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007, 67:2345-2350.
85. Kumar M.S., Lu J., Mercer K.L., Golub T.R., Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39:673-677.
86. Deng S., Calin G.A., Croce C.M., Coukos G., Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008, 7:2643-2646.
87. Lee Y., Kim M., Han J., Yeom K.H., Lee S., Baek S.H., Kim V.N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23:4051-4060.
88. Cai X., Hagedorn C.H., Cullen B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004, 10:1957-1966.
89. Lee Y., Jeon K., Lee J.T., Kim S., Kim V.N. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002, 21:4663-4670.
90. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Radmark O., Kim S., Kim V.N. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425:415-419.
91. Zeng Y., Yi R., Cullen B.R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9779-9784.
92. Basyuk E., Suavet F., Doglio A., Bordonne R., Bertrand E. Human let-7 stem-loop precursors harbor features of RNase III cleavage products. Nucleic Acids Res. 2003, 31:6593-6597.
93. Lund E., Guttinger S., Calado A., Dahlberg J.E., Kutay U. Nuclear export of microRNA precursors. Science 2004, 303:95-98.
94. Yi R., Qin Y., Macara I.G., Cullen B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17:3011-3016.
95. Bohnsack M.T., Czaplinski K., Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10:185-191.
96. Hutvagner G., McLachlan J., Pasquinelli A.E., Balint E., Tuschl T., Zamore P.D. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001, 293:834-838.
97. Knight S.W., Bass B.L. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. Science 2001, 293:2269-2271.
98. Hammond S.M., Boettcher S., Caudy A.A., Kobayashi R., Hannon G.J. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 2001, 293:1146-1150.
99. Hutvagner G., Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297:2056-2060.
100. Martinez J., Patkaniowska A., Urlaub H., Luhrmann R., Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002, 110:563-574.
101. Broderick J.A., Zamore P.D. MicroRNA therapeutics. Gene Ther. 2011, 18:1104-1110.
102. Lingel A., Simon B., Izaurralde E., Sattler M. Nucleic acid 3'-end recognition by the Argonaute2 PAZ domain. Nat. Struct. Mol. Biol. 2004, 11:576-577.
103. Cerutti L., Mian N., Bateman A. Domains in gene silencing and cell differentiation proteins: the novel PAZ domain and redefinition of the Piwi domain. Trends Biochem. Sci. 2000, 25:481-482.
104. Tay Y., Zhang J., Thomson A.M., Lim B., Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008, 455:1124-1128.
105. Lytle J.R., Yario T.A., Steitz J.A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9667-9672.
106. Orom U.A., Nielsen F.C., Lund A.H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 2008, 30:460-471.
107. Baek D., Villen J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
108. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
109. Bader A.G., Brown D., Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70:7027-7030.
110. Lennox K.A., Behlke M.A. A direct comparison of anti-microRNA oligonucleotide potency. Pharm. Res. 2010, 27:1788-1799.
111. Yu J., Ohuchida K., Mizumoto K., Fujita H., Nakata K., Tanaka M. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. Cancer Biol. Ther. 2010, 10:748-757.
112. Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., Leon L.G., Pollina L.E., Groen A., Falcone A., Danesi R., Campani D., Verheul H.M., Boggi U. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70:4528-4538.
113. Nakata K., Ohuchida K., Mizumoto K., Kayashima T., Ikenaga N., Sakai H., Lin C., Fujita H., Otsuka T., Aishima S., Nagai E., Oda Y., Tanaka M. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery 2011, 150:916-922.
114. Kong X., Du Y., Wang G., Gao J., Gong Y., Li L., Zhang Z., Zhu J., Jing Q., Qin Y., Li Z. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig. Dis. Sci. 2011, 56:602-609.
115. Moriyama T., Ohuchida K., Mizumoto K., Yu J., Sato N., Nabae T., Takahata S., Toma H., Nagai E., Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 2009, 8:1067-1074.
116. Hwang J.H., Voortman J., Giovannetti E., Steinberg S.M., Leon L.G., Kim Y.T., Funel N., Park J.K., Kim M.A., Kang G.H., Kim S.W., Del Chiaro M., Peters G.J., Giaccone G. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 2010, 5:e10630.
117. Singh S., Chitkara D., Kumar V., Behrman S.W., Mahato R.I. miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett. 2013, 334:211-220.
118. Mittal A., Chitkara D., Behrman S.W., Mahato R.I. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials 2014, 35:7077-7087.
119. Cai B., An Y., Lv N., Chen J., Tu M., Sun J., Wu P., Wei J., Jiang K., Miao Y. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Oncol. Rep. 2013, 29:1769-1776.
120. Zhu Z., Xu Y., Du J., Tan J., Jiao H. Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival. J. Surg. Oncol. 2014, 109:89-94.
121. Song W.F., Wang L., Huang W.Y., Cai X., Cui J.J., Wang L.W. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Asian Pac. J. Cancer Prev. 2013, 14:7529-7536.
122. Kadera B.E., Li L., Toste P.A., Wu N., Adams C., Dawson D.W., Donahue T.R. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS ONE 2013, 8:e71978.
123. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., Sarkar F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69:6704-6712.
124. Sung S.Y., Liao C.H., Wu H.P., Hsiao W.C., Wu I.H., Jinpu Yu, Lin S.H., Hsieh C.L. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS ONE 2013, 8:e71637.
125. Zhao Y., Deng C., Lu W., Xiao J., Ma D., Guo M., Recker R.R., Gatalica Z., Wang Z., Xiao G.G. Let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol. Med. 2011, 17:1233-1241.
126. Zhao Y., Deng C., Wang J., Xiao J., Gatalica Z., Recker R.R., Xiao G.G. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 2011, 127:69-80.
127. Hua S., Xiaotao X., Renhua G., Yongmei Y., Lianke L., Wen G., Yongqian S. Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. Biomed. Pharmacother. 2012, 66:89-97.
128. Zhong Z., Dong Z., Yang L., Chen X., Gong Z. Inhibition of proliferation of human lung cancer cells by green tea catechins is mediated by upregulation of let-7. Exp. Ther. Med. 2012, 4:267-272.
129. Trang P., Medina P.P., Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Homer R., Brown D., Bader A.G., Weidhaas J.B., Slack F.J. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29:1580-1587.
130. Liu C., Kelnar K., Vlassov A.V., Brown D., Wang J., Tang D.G. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res. 2012, 72:3393-3404.
131. Nadiminty N., Tummala R., Lou W., Zhu Y., Zhang J., Chen X., eVere White R.W., Kung H.J., Evans C.P., Gao A.C. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J. Biol. Chem. 2012, 287:1527-1537.
132. Haselmann V., Kurz A., Bertsch U., Hubner S., Olempska-Muller M., Fritsch J., Hasler R., Pickl A., Fritsche H., Annewanter F., Engler C., Fleig B., Bernt A., Roder C., Schmidt H., Gelhaus C., Hauser C., Egberts J.H., Heneweer C., Rohde A.M., Boger C., Knippschild U., Rocken C., Adam D., Walczak H., Schutze S., Janssen O., Wulczyn F.G., Wajant H., Kalthoff H., Trauzold A. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology 2014, 146:278-290.
133. Patel K., Kollory A., Takashima A., Sarkar S., Faller D.V., Ghosh S.K. MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Lett. 2014, 347:54-64.
134. Kobayashi M., Salomon C., Tapia J., Illanes S.E., Mitchell M.D., Rice G.E. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J. Transl. Med. 2014, 12. (4-5876-12-4).
135. Wendler A., Keller D., Albrecht C., Peluso J.J., Wehling M. Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. Oncol. Rep. 2011, 25:273-279.
136. Helland A., Anglesio M.S., George J., Cowin P.A., Johnstone C.N., House C.M., Sheppard K.E., Etemadmoghadam D., Melnyk N., Rustgi A.K., Phillips W.A., Johnsen H., Holm R., Kristensen G.B., Birrer M.J., Australian Ovarian Cancer Study Group, Pearson R.B., Borresen-Dale A.L., Huntsman D.G., deFazio A., Creighton C.J., Smyth G.K., Bowtell D.D. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS ONE 2011, 6:e18064.
137. Schultz J., Lorenz P., Gross G., Ibrahim S., Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008, 18:549-557.
138. Fu T.Y., Chang C.C., Lin C.T., Lai C.H., Peng S.Y., Ko Y.J., Tang P.C. Let-7b-mediated suppression of basigin expression and metastasis in mouse melanoma cells. Exp. Cell Res. 2011, 317:445-451.
139. Michl P., Gress T.M. Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid. Gut 2012, 61:1377-1379.
140. Schneiderhan W., Diaz F., Fundel M., Zhou S., Siech M., Hasel C., Moller P., Gschwend J.E., Seufferlein T., Gress T., Adler G., Bachem M.G. Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J. Cell Sci. 2007, 120:512-519.
141. Pasca di Magliano M., Sekine S., Ermilov A., Ferris J., Dlugosz A.A., Hebrok M. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev. 2006, 20:3161-3173.
142. Hamada S., Masamune A., Shimosegawa T. Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Front. Physiol. 2013, 4:331.
143. Hidalgo M., Maitra A. The hedgehog pathway and pancreatic cancer. N. Engl. J. Med. 2009, 361:2094-2096.
144. Li X., Ma Q., Duan W., Liu H., Xu H., Wu E. Paracrine sonic hedgehog signaling derived from tumor epithelial cells: a key regulator in the pancreatic tumor microenvironment. Crit. Rev. Eukaryot. Gene Expr. 2012, 22:97-108.
145. Ferretti E., De Smaele E., Miele E., Laneve P., Po A., Pelloni M., Paganelli A., Di Marcotullio L., Caffarelli E., Screpanti I., Bozzoni I., Gulino A. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 2008, 27:2616-2627.
146. Tsuda N., Ishiyama S., Li Y., Ioannides C.G., Abbruzzese J.L., Chang D.Z. Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. Clin. Cancer Res. 2006, 12:6557-6564.
147. Toole B.P., Slomiany M.G. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin. Cancer Biol. 2008, 18:244-250.
148. Thompson C.B., Shepard H.M., O'Connor P.M., Kadhim S., Jiang P., Osgood R.J., Bookbinder L.H., Li X., Sugarman B.J., Connor R.J., Nadjsombati S., Frost G.I. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 2010, 9:3052-3064.
149. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., Feig C., Nakagawa T., Caldwell M.E., Zecchini H.I., Lolkema M.P., Jiang P., Kultti A., Thompson C.B., Maneval D.C., Jodrell D.I., Frost G.I., Shepard H.M., Skepper J.N., Tuveson D.A. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62:112-120.
150. Diop-Frimpong B., Chauhan V.P., Krane S., Boucher Y., Jain R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2909-2914.
151. Merika E.E., Syrigos K.N., Saif M.W. Desmoplasia in pancreatic cancer. Can we fight it?. Gastroenterol. Res. Pract. 2012, 1-10.
152. Shields M.A., Dangi-Garimella S., Krantz S.B., Bentrem D.J., Munshi H.G. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J. Biol. Chem. 2011, 286:10495-10504.
153. Dangi-Garimella S., Strouch M.J., Grippo P.J., Bentrem D.J., Munshi H.G. Collagen regulation of let-7 in pancreatic cancer involves TGF-β1-mediated membrane type 1-matrix metalloproteinase expression. Oncogene 2011, 30:1002-1008.
154. Takikawa T., Masamune A., Hamada S., Nakano E., Yoshida N., Shimosegawa T. miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Biochem. Biophys. Res. Commun. 2013, 437:433-439.
155. Aprelikova O., Yu X., Palla J., Wei B.R., John S., Yi M., Stephens R., Simpson R.M., Risinger J.I., Jazaeri A., Niederhuber J. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle 2010, 9:4387-4398.
156. Izumiya M., Kabashima A., Higuchi H., Igarashi T., Sakai G., Iizuka H., Nakamura S., Adachi M., Hamamoto Y., Funakoshi S., Takaishi H., Hibi T. Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. Anticancer Res. 2012, 32:3847-3853.
157. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
158. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
159. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., Waldvogel B., Vannier C., Darling D., zur Hausen A., Brunton V.G., Morton J., Sansom O., Schuler J., Stemmler M.P., Herzberger C., Hopt U., Keck T., Brabletz S., Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11:1487-1495.
160. Hamada S., Satoh K., Fujibuchi W., Hirota M., Kanno A., Unno J., Masamune A., Kikuta K., Kume K., Shimosegawa T. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol. Cancer Res. 2012, 10:3-10.
161. Hamada S., Satoh K., Miura S., Hirota M., Kanno A., Masamune A., Kikuta K., Kume K., Unno J., Egawa S., Motoi F., Unno M., Shimosegawa T. miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J. Cell. Physiol. 2013, 228:1255-1263.
162. Sureban S.M., May R., Lightfoot S.A., Hoskins A.B., Lerner M., Brackett D.J., Postier R.G., Ramanujam R., Mohammed A., Rao C.V., Wyche J.H., Anant S., Houchen C.W. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011, 71:2328-2338.
163. Boutla A., Delidakis C., Tabler M. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identification of putative target genes. Nucleic Acids Res. 2003, 31:4973-4980.
164. Lennox K.A., Behlke M.A. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 2011, 18:1111-1120.
165. Lennox K.A., Sabel J.L., Johnson M.J., Moreira B.G., Fletcher C.A., Rose S.D., Behlke M.A., Laikhter A.L., Walder J.A., Dagle J.M. Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. Oligonucleotides 2006, 16:26-42.
166. Meister G., Landthaler M., Dorsett Y., Tuschl T. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 2004, 10:544-550.
167. Freier S.M., Altmann K.H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 1997, 25:4429-4443.
168. Esau C., Kang X., Peralta E., Hanson E., Marcusson E.G., Ravichandran L.V., Sun Y., Koo S., Perera R.J., Jain R., Dean N.M., Freier S.M., Bennett C.F., Lollo B., Griffey R. MicroRNA-143 regulates adipocyte differentiation. J. Biol. Chem. 2004, 279:52361-52365.
169. Hutvagner G., Simard M.J., Mello C.C., Zamore P.D. Sequence-specific inhibition of small RNA function. PLoS Biol. 2004, 2:E98.
170. Eder P.S., DeVine R.J., Dagle J.M., Walder J.A. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. Antisense Res. Dev. 1991, 1:141-151.
171. Vermeulen A., Robertson B., Dalby A.B., Marshall W.S., Karpilow J., Leake D., Khvorova A., Baskerville S. Double-stranded regions are essential design components of potent inhibitors of RISC function. RNA 2007, 13:723-730.
172. Davis S., Propp S., Freier S.M., Jones L.E., Serra M.J., Kinberger G., Bhat B., Swayze E.E., Bennett C.F., Esau C. Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res. 2009, 37:70-77.
173. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
174. Krutzfeldt J., Kuwajima S., Braich R., Rajeev K.G., Pena J., Tuschl T., Manoharan M., Stoffel M. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 2007, 35:2885-2892.
175. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., Galuppo P., Just S., Rottbauer W., Frantz S., Castoldi M., Soutschek J., Koteliansky V., Rosenwald A., Basson M.A., Licht J.D., Pena J.T., Rouhanifard S.H., Muckenthaler M.U., Tuschl T., Martin G.R., Bauersachs J., Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
176. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., Teruya-Feldstein J., Bell G.W., Weinberg R.A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28:341-347.
177. Petersen M., Bondensgaard K., Wengel J., Jacobsen J.P. Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids. J. Am. Chem. Soc. 2002, 124:5974-5982.
178. Petersen M., Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol. 2003, 21:74-81.
179. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65:6029-6033.
180. Naguibneva I., Ameyar-Zazoua M., Polesskaya A., Ait-Si-Ali S., Groisman R., Souidi M., Cuvellier S., Harel-Bellan A. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat. Cell Biol. 2006, 8:278-284.
181. Fabani M.M., Gait M.J. miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 2008, 14:336-346.
182. Bauman J., Jearawiriyapaisarn N., Kole R. Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 2009, 19:1-13.
183. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004, 64:3365-3370.
184. van de Water F.M., Boerman O.C., Wouterse A.C., Peters J.G., Russel F.G., Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos. 2006, 34:1393-1397.
185. Lin Q., Chen J., Zhang Z., Zheng G. Lipid-based nanoparticles in the systemic delivery of siRNA. Nanomedicine (London) 2014, 9:105-120.
186. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9:615-627.
187. Conner S.D., Schmid S.L. Regulated portals of entry into the cell. Nature 2003, 422:37-44.
188. Wu Y., Crawford M., Yu B., Mao Y., Nana-Sinkam S.P., Lee L.J. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 2011, 8:1381-1389.
189. Ozpolat B., Sood A.K., Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv. Drug Deliv. Rev. 2014, 66:110-116.
190. Felgner J.H., Kumar R., Sridhar C.N., Wheeler C.J., Tsai Y.J., Border R., Ramsey P., Martin M., Felgner P.L. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 1994, 269:2550-2561.
191. Gruneich J.A., Price A., Zhu J., Diamond S.L. Cationic corticosteroid for nonviral gene delivery. Gene Ther. 2004, 11:668-674.
192. Singh R.S., Chaudhuri A. Single additional methylene group in the head-group region imparts high gene transfer efficacy to a transfection-incompetent cationic lipid. FEBS Lett. 2004, 556:86-90.
193. Mahidhar Y.V., Rajesh M., Chaudhuri A. Spacer-arm modulated gene delivery efficacy of novel cationic glycolipids: design, synthesis, and in vitro transfection biology. J. Med. Chem. 2004, 47:3938-3948.
194. Shi N., Zhang Y., Zhu C., Boado R.J., Pardridge W.M. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12754-12759.
195. Templeton N.S., Lasic D.D., Frederik P.M., Strey H.H., Roberts D.D., Pavlakis G.N. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 1997, 15:647-652.
196. Mukherjee K., Sen J., Chaudhuri A. Common co-lipids, in synergy, impart high gene transfer properties to transfection-incompetent cationic lipids. FEBS Lett. 2005, 579:1291-1300.
197. Piao L., Zhang M., Datta J., Xie X., Su T., Li H., Teknos T.N., Pan Q. Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol. Ther. 2012, 20:1261-1269.
198. Wu Y., Crawford M., Mao Y., Lee R.J., Davis I.C., Elton T.S., Lee L.J., Nana-Sinkam S.P. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. Mol. Ther. Nucleic Acids 2013, 2:e84.
199. Devine D.V., Wong K., Serrano K., Chonn A., Cullis P.R. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim. Biophys. Acta 1994, 1191:43-51.
200. Chonn A., Cullis P.R., Devine D.V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 1991, 146:4234-4241.
201. Plank C., Mechtler K., Szoka F.C., Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum. Gene Ther. 1996, 7:1437-1446.
202. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., Wiggins J.F., Bader A.G., Fagin R., Brown D., Tang D.G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
203. Toncheva V., Wolfert M.A., Dash P.R., Oupicky D., Ulbrich K., Seymour L.W., Schacht E.H. Novel vectors for gene delivery formed by self-assembly of DNA with poly(l-lysine) grafted with hydrophilic polymers. Biochim. Biophys. Acta 1998, 1380:354-368.
204. Jin H., Yu Y., Chrisler W.B., Xiong Y., Hu D., Lei C. Delivery of microRNA-10b with polylysine nanoparticles for inhibition of breast cancer cell wound healing. Breast Cancer (Auckl.) 2012, 6:9-19.
205. Ward C.M., Read M.L., Seymour L.W. Systemic circulation of poly(l-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood 2001, 97:2221-2229.
206. Dash P.R., Read M.L., Barrett L.B., Wolfert M.A., Seymour L.W. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther. 1999, 6:643-650.
207. Sonawane N.D., Szoka F.C., Verkman A.S. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 2003, 278:44826-44831.
208. Yamagata M., Kawano T., Shiba K., Mori T., Katayama Y., Niidome T. Structural advantage of dendritic poly(l-lysine) for gene delivery into cells. Bioorg. Med. Chem. 2007, 15:526-532.
209. Pouton C.W., Lucas P., Thomas B.J., Uduehi A.N., Milroy D.A., Moss S.H. Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J. Control. Release 1998, 53:289-299.
210. Midoux P., Monsigny M. Efficient gene transfer by histidylated polylysine/pDNA complexes. Bioconjug. Chem. 1999, 10:406-411.
211. Mannisto M., Vanderkerken S., Toncheva V., Elomaa M., Ruponen M., Schacht E., Urtti A. Structure-activity relationships of poly(l-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J. Control. Release 2002, 83:169-182.
212. Nishikawa M., Takemura S., Takakura Y., Hashida M. Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(l-lysine) complexes by controlling their physicochemical properties. J. Pharmacol. Exp. Ther. 1998, 287:408-415.
213. Wolfert M.A., Dash P.R., Nazarova O., Oupicky D., Seymour L.W., Smart S., Strohalm J., Ulbrich K. Polyelectrolyte vectors for gene delivery: influence of cationic polymer on biophysical properties of complexes formed with DNA. Bioconjug. Chem. 1999, 10:993-1004.
214. Fischer D., Bieber T., Li Y., Elsasser H.P., Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res. 1999, 16:1273-1279.
215. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24:1121-1131.
216. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 2006, 114:100-109.
217. Ferrari S., Moro E., Pettenazzo A., Behr J.P., Zacchello F., Scarpa M. ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Ther. 1997, 4:1100-1106.
218. Han S., Mahato R.I., Kim S.W. Water-soluble lipopolymer for gene delivery. Bioconjug. Chem. 2001, 12:337-345.
219. Mahato R.I., Lee M., Han S., Maheshwari A., Kim S.W. Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol. Ther. 2001, 4:130-138.
220. Cheng C.J., Saltzman W.M. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol. Pharm. 2012, 9:1481-1488.
221. Devalliere J., Chang W.G., Andrejecsk J.W., Abrahimi P., Cheng C.J., Jane-wit D., Saltzman W.M., Pober J.S. Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation. FASEB J. 2014, 28:908-922.
222. Wang D., Robinson D.R., Kwon G.S., Samuel J. Encapsulation of plasmid DNA in biodegradable poly(d,l-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J. Control. Release 1999, 57:9-18.
223. Luo D., Woodrow-Mumford K., Belcheva N., Saltzman W.M. Controlled DNA delivery systems. Pharm. Res. 1999, 16:1300-1308.
224. Cheng C.J., Saltzman W.M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials 2011, 32:6194-6203.
225. Anand S., Majeti B.K., Acevedo L.M., Murphy E.A., Mukthavaram R., Scheppke L., Huang M., Shields D.J., Lindquist J.N., Lapinski P.E., King P.D., Weis S.M., Cheresh D.A. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat. Med. 2010, 16:909-914.
226. Yigit M., Ghosh S., Zdravka Medarova Z., Moore A.V. Abstract 2952: Image-guided miRNA therapy for metastatic breast cancer. Cancer Res. 2011, 72:2952.
227. Zhou Y., Zhang L., Zhao W., Wu Y., Zhu C., Yang Y. Nanoparticle-mediated delivery of TGF-beta1 miRNA plasmid for preventing flexor tendon adhesion formation. Biomaterials 2013, 34:8269-8278.
228. Kim H.O., Kim E., An Y., Choi J., Jang E., Choi E.B., Kukreja A., Kim M.H., Kang B., Kim D.J., Suh J.S., Huh Y.M., Haam S. A biodegradable polymersome containing Bcl-xL siRNA and doxorubicin as a dual delivery vehicle for a synergistic anticancer effect. Macromol. Biosci. 2013, 13:745-754.
229. Cheng G., Danquah M., Mahato R. MicroRNAs as therapeutic targets for cancer. Pharmaceutical Perspectives of Cancer Therapeutics 2009, 441-474. Springer Science{thorn}Business Media, LLC, USA. Y. Lu, R. Mahato (Eds.).
230. De Paula D., Bentley M.V., Mahato R.I. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007, 13:431-456.
231. Juliano R.L., Ming X., Nakagawa O. The chemistry and biology of oligonucleotide conjugates. Acc. Chem. Res. 2012, 45:1067-1076.
232. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A.J., Patick A.K., Chen A., Zhou Y., Persson R., King B.D., Kauppinen S., Levin A.A., Hodges M.R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368:1685-1694.
233. Santaris Pharma A/S Drug interaction study to assess the effect of co-administered miravirsen and teleprevir in healthy subjects 2012, ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda, MD, ([Cited May 05, 2014] NLM identifier: NCT001646489).
234. Santaris Pharma A/S Miravirsen in combination with telaprevir and ribavirin in null responder to pegylated-interferon alpha plus ribavirin subjects with chronic hepatitis C virus infection 2013, ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda, MD, ([Cited July 19, 2013] NLM identifier: NCT01872936).
235. Santaris Pharma A/S Miravirsen study in null responder to pegylated interferon alpha plus ribavirin subjects with chronic hepatitis C 2012, ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda, MD, ([Cited May 05, 2014] NLM identifier: NCT01727934).
236. Santaris Pharma A/S SPC3649 multiple dose study in healthy volunteers 2009-2011, ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda, MD, ([Cited May 05, 2014] NLM identifier: NCT00979927).
237. Santaris Pharma A/S Safety study of SPC3649 in healthy men 2008-2009, ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda, MD, ([Cited May 05, 2014] NLM identifier: NCT00688012).
238. Mirna Therapeutics Inc. A phase 1 study of MRX34 given intravenously in patients with unresectable primary liver cancer or metastatic cancer with liver involvement 2013, ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda, MD, ([Cited May 05, 2014] NLM identifier: NCT01829971).
239. Ivanovska I., Cleary M.A. Combinatorial microRNAs: working together to make a difference. Cell Cycle 2008, 7:3137-3142.